BDFS Capital LLC Takes Position in Cencora, Inc. $COR

BDFS Capital LLC bought a new position in shares of Cencora, Inc. (NYSE:COR) during the fourth quarter, Holdings Channel reports. The firm bought 2,461 shares of the company’s stock, valued at approximately $831,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its holdings in Cencora by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 23,617,117 shares of the company’s stock worth $7,976,681,000 after buying an additional 221,570 shares during the last quarter. State Street Corp boosted its stake in Cencora by 1.3% in the fourth quarter. State Street Corp now owns 9,305,507 shares of the company’s stock valued at $3,142,935,000 after acquiring an additional 115,191 shares during the last quarter. T. Rowe Price Investment Management Inc. boosted its stake in Cencora by 160.1% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock valued at $2,262,956,000 after acquiring an additional 4,123,795 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Cencora by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 5,459,476 shares of the company’s stock valued at $1,843,268,000 after acquiring an additional 169,055 shares during the period. Finally, JPMorgan Chase & Co. grew its position in shares of Cencora by 6.5% during the 4th quarter. JPMorgan Chase & Co. now owns 4,982,557 shares of the company’s stock valued at $1,682,859,000 after acquiring an additional 304,760 shares during the period. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Performance

NYSE COR opened at $271.99 on Friday. The firm has a market cap of $52.92 billion, a P/E ratio of 20.86, a price-to-earnings-growth ratio of 1.50 and a beta of 0.59. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40. The company’s 50 day moving average is $285.65 and its 200-day moving average is $324.72. Cencora, Inc. has a 12-month low of $244.82 and a 12-month high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing the consensus estimate of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. During the same period last year, the business posted $4.42 earnings per share. The firm’s quarterly revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Sell-side analysts predict that Cencora, Inc. will post 17.79 earnings per share for the current year.

Cencora announced that its board has initiated a share repurchase plan on Thursday, May 21st that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the company to repurchase up to 3.9% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its stock is undervalued.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were given a dividend of $0.60 per share. The ex-dividend date was Friday, May 15th. This represents a $2.40 annualized dividend and a dividend yield of 0.9%. Cencora’s dividend payout ratio is currently 18.40%.

Wall Street Analysts Forecast Growth

COR has been the topic of a number of research reports. Evercore set a $360.00 price target on shares of Cencora in a report on Wednesday, April 8th. William Blair began coverage on Cencora in a report on Tuesday, April 28th. They set a “market perform” rating for the company. Weiss Ratings downgraded Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 22nd. Barclays lowered their target price on Cencora from $425.00 to $350.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 10th. Finally, Wells Fargo & Company dropped their price target on Cencora from $429.00 to $331.00 and set an “overweight” rating on the stock in a research report on Monday, May 11th. Twelve investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and an average price target of $374.00.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.